Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Illumina, Inc. - Common Stock (NQ:ILMN)

94.49 +1.49 (+1.60%)
Streaming Delayed Price Updated: 9:38 AM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Illumina, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
34 35 Next >
3 Nasdaq-100 Stocks Trading Less Than 10x 2024 Earnings
These three Nasdaq-100 stocks can be had for less than 10x 2024 earnings - extra compelling given that Wall Street expects Nasdaq profits will grow next year. 
Via MarketBeat
Topics Bonds Economy
Where Illumina Stands With Analysts
 
Via Benzinga
ChatGPT Parent OpenAI Aims At Budget-Friendly AI Innovations, Novo Nordisk's Popular Diabetes Drug Ozempic Faces Counterfeit Threat in Germany: Today's Top Stories
Bloomberg Apple and Suppliers Face Unanticipated Sales Slump Despite New Launches 
Via Benzinga
Topics Artificial Intelligence Supply Chain
Will Illumina Give Up Cancer Test Maker Grail? Mulls $8B Acquisition's Fate Amid Antitrust Pressure
Illumina Inc (NASDAQ: ILMN) reportedly said it will divest its controversial acquisition of Grail as expeditiously as possible if the life sciences company loses either of the final appeals in U.S. or... 
Via Benzinga
Expert Ratings for Illumina
 
Via Benzinga
How Is The Market Feeling About Illumina?
 
Via Benzinga
Is the Worst Over for Illumina Stock?
There's reason to believe that the future is starting to look better. 
Via The Motley Fool
$100 Invested In Illumina 20 Years Ago Would Be Worth This Much Today
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Bear Of The Day: Illumina
Illumina, the maker of million-dollar genome sequencing machines that revolutionized the fields of genetics and biotechnology, has fallen hard in the past year. 
Via Talk Markets
Illumina Faces Mounting Pressure from Regulators Over $8B Grail Acquisition
The European Union regulators are set to order Illumina Inc (NASDAQ: ILMN) to divest its acquisition of  
Via Benzinga
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
As the healthcare sector slumps, several major stocks, including Zimmer Biomet, Moderna, and Illumina, appear undervalued in contrast to their intrinsic worth. 
Via MarketBeat
11 Analysts Have This to Say About Illumina
 
Via Benzinga
Peering Into Illumina's Recent Short Interest
 
Via Benzinga
Here's How Much You Would Have Made Owning Illumina Stock In The Last 20 Years
 
Via Benzinga
Lowey Dannenberg, P.C. is Investigating Illumina, Inc. (NASDAQ: ILMN) for Potential Breaches of Fiduciary Duty by Its Board of Directors
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Illumina, Inc. (NASDAQ: ILMN) for Potential Breaches of Fiduciary Duty by Its Board of Directors
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Nike To Rally Around 53%? Here Are 10 Other Analyst Forecasts For Friday
Piper Sandler cut the price target for Accenture plc (NYSE: ACN) from $312 to $300. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Accenture shares rose 0.3% to $301.56 in pre-market... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
 
Via Benzinga
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
The September market downturn is spreading like wildfire across various sectors, with only a handful of stocks managing to maintain the positive trend seen in recent months. 
Via Benzinga
Topics Stocks
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test 
From Myriad Genetics, Inc.
Via GlobeNewswire
Cramer Is 'Astonished' That Chewy Is 'Doing This Poorly — So Many Of Us Use It'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said yes to The St. Joe Company (NYSE: JOE). "I’ve liked St. Joe forever," he added. 
Via Benzinga
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
Did Elon Musk Admit 90% Decline In Twitter's Value Since Acquisition?, Apple's Zero-Click Vulnerabilities Uncovered By Internet Watchdog Group, Gas Prices Jump As Strikes Start At Major Chevron Australia LNG Projects: Today's Top Stories
Benzinga 
Via Benzinga
Billionaire Activist Investor Carl Icahn Shows Support For Illumina's Newly Appointed CEO
Activist investor Carl Icahn has thrown his support behind Illumina Inc's (NASDAQ: ILMN) new CEO, Jacob Thaysen, providing a sigh of relief for the company as it strives to recover from a contentious... 
Via Benzinga
Cathie Wood's Buying These 3 Stocks Hand Over Fist
A drugmaker, a gene sequencer, and a streaming business all made deep impressions on Ark Invest's stock-picking team. 
Via The Motley Fool
Why Is Illumina Stock Trading Lower Today?
Illumina Inc (NASDAQ: ILMN) shares are trading lower after the company appointed Jacob Thaysen as its new CEO, roughly three months after the company parted ways  
Via Benzinga
Goldman Sachs Reveals Long-Term AI Portfolio: Here Are The 50 Stocks To Monitor
 
Via Benzinga
Topics Artificial Intelligence
Wall Street Thinks Illumina Stock Will Rise 27% in 1 Year. Here's Why That Probably Won't Happen.
Its core revenue won't grow, and that's not even its biggest problem at the moment. 
Via The Motley Fool
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.